Release form
Rectal suppositories.
Packing
10 pcs.
Pharmacological action
Interferon alfa-2b human recombinant has antiviral, immunomodulating, antiproliferative properties, inhibits the replication of RNA and DNA viruses. The immunomodulating properties of interferon alpha-2b, such as increased macrophage phagocytic activity, increased specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity.
In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which improves the efficiency of the body's own immune response to pathogenic microorganisms. When using the drug, the level of secretory immunoglobulins of class A increases, the level of immunoglobulin E is normalized, the functioning of the endogenous system of interferon alpha-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and also regenerating properties. It has been established that when using the VIFERON® preparation, there are no side effects arising from the parenteral administration of interferon alpha-2b preparations, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b. The use of VIFERON® as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.
Cocoa butter contains phospholipids that prevent synthetic toxic emulsifiers from being used in production, and the presence of polyunsaturated fatty acids facilitates the administration and dissolution of the drug.
Indications
- acute respiratory viral infections, including influenza, including complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of the complex therapy
- infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of a complex therapy II
- chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in case of severe viral hepatitis, complicated by cirrhosis of the liver mucous membranes, localized form, mild and moderate course, including the urogenital form in adults.
Contraindications
Hypersensitivity to any component of the drug.
Special instructions
For the treatment of a wide range of infectious and inflammatory diseases Viferon can be used as part of combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs.
There is evidence of the effectiveness of the use of Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpetic infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children over 1 year old, viral hepatitis in adults, SARS, influenza, bronchial asthma, juvenile rheumatoid arthritis meningeal form of tick-borne encephalitis prostatitis of various etiologies purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephus rits.
Composition
1 suppository VIFERONΠ150,000 IU contains the active substance: interferon alpha-2b human recombinant 150,000 IU, excipients: ascorbic acid 0.0054 g, sodium ascorbate 0.0108 g, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g, polysorbate-80 0.0001 g, cocoa butter 0.1958 g, confectionery fat or cocoa butter substitute up to 1 g
Side effects
In rare cases, the development of allergic reactions (skin rashes, itching) is possible. These phenomena are reversible and disappear after 72 hours after stopping the drug.
Drug interaction
VIFERON®, rectal suppositories, is compatible and well combined with all drugs used in the treatment of the above diseases (antibiotics, chemotherapy, glucocorticosteroids).
Storage Conditions
The product should be stored dry, protected from light at 2 ° to 8 РC.
Expiration
2 years.
Active ingredient
Interferon alfa-2b
Terms leave through pharmacies
without prescription
lekarstvennaja form
suppozytoryy rektaln e
Indications
Vaginal candidiasis, influenza, hepatitis, herpes, urinary tract infections, Chlamydia, vaginal infection, HPV
Possible product names
Viferon 1 150 thousand. ME № 10 supp
Viferon 1 supp. rect. 150tys.ME N10 Russia
Viferon 150,000 IU Supp. rect. X10 (R)
Viferon ointment 40,000 IU / g, 12 g
Viferon rectal suppositories 150,000 IU, 10 pcs.
Fearon, Russia
Rectal suppositories.
Packing
10 pcs.
Pharmacological action
Interferon alfa-2b human recombinant has antiviral, immunomodulating, antiproliferative properties, inhibits the replication of RNA and DNA viruses. The immunomodulating properties of interferon alpha-2b, such as increased macrophage phagocytic activity, increased specific cytotoxicity of lymphocytes to target cells, determine its mediated antibacterial activity.
In the presence of ascorbic acid and alpha-tocopherol acetate, the specific antiviral activity of interferon alpha-2b increases, its immunomodulatory effect is enhanced, which improves the efficiency of the body's own immune response to pathogenic microorganisms. When using the drug, the level of secretory immunoglobulins of class A increases, the level of immunoglobulin E is normalized, the functioning of the endogenous system of interferon alpha-2b is restored. Ascorbic acid and alpha-tocopherol acetate, being highly active antioxidants, have anti-inflammatory, membrane-stabilizing, and also regenerating properties. It has been established that when using the VIFERON® preparation, there are no side effects arising from the parenteral administration of interferon alpha-2b preparations, antibodies are not formed that neutralize the antiviral activity of interferon alpha-2b. The use of VIFERON® as part of complex therapy allows to reduce therapeutic doses of antibacterial and hormonal drugs, as well as reduce the toxic effects of this therapy.
Cocoa butter contains phospholipids that prevent synthetic toxic emulsifiers from being used in production, and the presence of polyunsaturated fatty acids facilitates the administration and dissolution of the drug.
Indications
- acute respiratory viral infections, including influenza, including complicated by a bacterial infection, pneumonia (bacterial, viral, chlamydial) in children and adults as part of the complex therapy
- infectious and inflammatory diseases of newborns, including premature infants: meningitis (bacterial, viral), sepsis, intrauterine infection (chlamydia, herpes, cytomegalovirus infection, enterovirus infection, candidiasis, including visceral, mycoplasmosis) as part of a complex therapy II
- chronic viral hepatitis B, C, D in children and adults as part of complex therapy, including in combination with the use of plasmapheresis and hemosorption in case of severe viral hepatitis, complicated by cirrhosis of the liver mucous membranes, localized form, mild and moderate course, including the urogenital form in adults.
Contraindications
Hypersensitivity to any component of the drug.
Special instructions
For the treatment of a wide range of infectious and inflammatory diseases Viferon can be used as part of combination therapy with antibacterial drugs, glucocorticoids, immunosuppressive drugs.
There is evidence of the effectiveness of the use of Viferon as part of complex therapy and for the prevention of the following diseases and conditions: herpetic infections, chlamydia, ureaplasmosis, toxoplasmosis, cytomegalovirus infection in adults and children over 1 year old, viral hepatitis in adults, SARS, influenza, bronchial asthma, juvenile rheumatoid arthritis meningeal form of tick-borne encephalitis prostatitis of various etiologies purulent-septic postoperative complications, virus-associated glomerulonephritis, pyelonephus rits.
Composition
1 suppository VIFERONΠ150,000 IU contains the active substance: interferon alpha-2b human recombinant 150,000 IU, excipients: ascorbic acid 0.0054 g, sodium ascorbate 0.0108 g, alpha-tocopherol acetate 0.055 g, disodium edetate dihydrate 0.0001 g, polysorbate-80 0.0001 g, cocoa butter 0.1958 g, confectionery fat or cocoa butter substitute up to 1 g
Side effects
In rare cases, the development of allergic reactions (skin rashes, itching) is possible. These phenomena are reversible and disappear after 72 hours after stopping the drug.
Drug interaction
VIFERON®, rectal suppositories, is compatible and well combined with all drugs used in the treatment of the above diseases (antibiotics, chemotherapy, glucocorticosteroids).
Storage Conditions
The product should be stored dry, protected from light at 2 ° to 8 РC.
Expiration
2 years.
Active ingredient
Interferon alfa-2b
Terms leave through pharmacies
without prescription
lekarstvennaja form
suppozytoryy rektaln e
Indications
Vaginal candidiasis, influenza, hepatitis, herpes, urinary tract infections, Chlamydia, vaginal infection, HPV
Possible product names
Viferon 1 150 thousand. ME № 10 supp
Viferon 1 supp. rect. 150tys.ME N10 Russia
Viferon 150,000 IU Supp. rect. X10 (R)
Viferon ointment 40,000 IU / g, 12 g
Viferon rectal suppositories 150,000 IU, 10 pcs.
Fearon, Russia
Related Products
